Drugs / HS-20089
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06769425 | May 2025 → May 2026 overdue | female breast carcinoma, gastric cancer, ovarian cancer, prostate cancer +1 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT06336707 | Apr 2024 → Apr 2026 overdue | cancer | Hansoh BioMedical R&D Company | Recruiting | No outcome recorded |
| Phase 1 | NCT05263479 | Jan 2022 → Dec 2024 overdue | neoplasm | Shanghai Hansoh Biomedical Co., Ltd | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06014190 | Dec 2023 → Dec 2025 overdue | endometrial cancer, fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma | Hansoh BioMedical R&D Company | Recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07821606 | Nov 2026 → Dec 2029 expected | — | Hansoh BioMedical R&D Company | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06855069 | Mar 2025 → Mar 2027 expected | ovarian carcinoma | Hansoh BioMedical R&D Company | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 9
| Date | Issuer | Release |
|---|---|---|
| 2026-03-02 | Hansoh BioMedical R&D Company | Results ESGO 2026 | 翰森制药Mocertatug Rezetecan（B7-H4 ADC）治疗铂敏感复发卵巢癌研究数据发布，其中一项研究入选LBA hansoh.cn ↗
Mocertatug rezetecan作为单药治疗及与贝伐珠单抗联合用药，在重度经治的铂敏感复发卵巢癌（PSOC）患者中显示出抗肿瘤活性，安全性可控. |
| 2026-02-28 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Results ESGO 2026 | HANSOH PHARMA PRESENTED DATA FOR MOCERTATUG REZETECAN (HS-20089,A B7-H4-TARGETED ADC) IN PATIENTS WITH PLATINUM-SENSITIVE OVARIAN CANCER,WITH ONE STUDY SELECTED AS LBA hspharm.com ↗
Across the two studies, mocertatug rezetecan showed anti-tumor activity with a safety profile consistent with previous studies. |
| 2025-11-10 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Results HANSOH PHARMA ANNOUNCES ORAL PRESENTATION OF PHASE 2 STUDY FINDINGS OF HS-20089 (B7-H4 ADC) IN PLATINUM-RESISTANT OVARIAN CANCER AT IGCS 2025 hspharm.com ↗
As of the June 20, 2025 data cutoff, HS-20089 is the first B7-H4 ADC to demonstrate promising efficacy in heavily pretreated patients with platinum-resistant ovarian cancer (PROC) who were not selected based on tumor B7-H4 expression. |
| 2025-10-20 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Results ESMO 2025 | HANSOH PHARMA PRESENTS THE PHASE 2 STUDY FINDINGS OF HS-20089 (B7-H4-TARGETED ADC), IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER (PROC) hspharm.com ↗
HS-20089 (licensed to GSK as GSK5733584) is the first B7-H4-directed antibody-drug conjugate (ADC) to demonstrate promising efficacy in heavily pretreated patients with platinum-resistant ovarian cancer (PROC) who were not selected based on tumor B7-H4 expression, with a confirmed ORR of 48.5% and DoR of 6.8 months，a median PFS (mPFS) of 6.4 months and a mOS of 14.6 months at the dose of 4.8mg/kg. |
| 2025-10-20 | Hansoh BioMedical R&D Company | Results ESMO | 翰森制药HS-20089(B7-H4 ADC)用于铂耐药卵巢癌（PROC）患者治疗的Ⅱ期研究结果发布 hansoh.cn ↗
HS-20089注射液在PROC患者中显示出良好的疗效，确认的客观缓解率（ORR）为48. 5%，缓解持续时间（DoR）为6. 8个月，中位无进展生存期（mPFS）为6. 4个月，中位总生存期（mOS）为14. 6个月. |
| 2025-05-02 | Hansoh BioMedical R&D Company | Regulatory 翰森制药B7-H4 ADC获NMPA纳入突破性治疗药物，用于铂耐药卵巢癌治疗 hansoh.cn ↗
注射用HS-20089获国家药品监督管理局（NMPA）批准纳入“突破性治疗药物” |
| 2025-05-01 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Regulatory HANSOH PHARMA ANNOUNCES NMPA HAS INCLUDED B7-H4-TARGETED ADC HS-20089 AS BREAKTHROUGH-THERAPY-DESIGNATED DRUG FOR PLATINUM-RESISTANT RECURRENT OVARIAN CANCER hspharm.com ↗ |
| 2023-10-19 | Hansoh BioMedical R&D Company | Results 2023 ESMO | 翰森制药携多项重要研究成果亮相，再攀国际学术高峰 hansoh.cn ↗ |
| 2021-07-15 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Regulatory HANSOH PHARMA'S IND APPLICATION FOR TWO CLASS 1 BIOLOGICAL INNOVATIVE DRUGS ACCEPTED hspharm.com ↗
Recently, the investigational new drug （IND） application for HS-20089 （for injection） and HS-20093 （for injection）， two new Class 1 therapeutic biological products independently developed by Shanghai Hansoh BioMedical Co., Ltd. under Hansoh Pharma （3692.HK）， was accepted and publicized by the National Medical Products Administration （NMPA）。 |
All press releases naming this drug 11 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS-20089 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06336707 ↗ |
| Action | Inhibit | “it inhibited tumor cell growth expressing B7-H4 in vitro and in vivo.” NCT05263479 ↗ |
| Modality | Monoclonal antibody | “humanized IgG1 anti-B7-H4 monoclonal antibody” NCT06336707 ↗ |
| Route | Intravenous | “IV administration of HS-20089 Q3W” NCT05263479 ↗ |